{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000091","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.015709+00:00","generated_at":"2026-06-13T05:39:51.443001+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design","bullets":["Announced interim data from open-label extension of seralutinib in PAH patients.","Detailed design of planned Phase 3 PROSERA trial for seralutinib.","No specific efficacy or safety numbers disclosed in the filing or exhibit.","Corporate presentation furnished as Exhibit 99.1 contains the update."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000091","json":"https://secwatch.observer/filing/0001728117-23-000091.json","markdown":"https://secwatch.observer/filing/0001728117-23-000091.md","text":"https://secwatch.observer/filing/0001728117-23-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/0001728117-23-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/goss-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:39:51.443001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}